Effects of orlistat on obesity‐related diseases – a six‐month randomized trial

Guy‐Grand, Bernard; Drouin, P; Eschwège, É.; Gin, H.; Jm, Joubert; Valensi, P.

doi:10.1111/j.1462-8902.2004.00359.x

Cited by 36 publications

(30 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We investigated obese patients over the first 3 months because in studies carried out on obesity, weight loss in these patients was often observed over the first 3 months, while it diminished dramatically after this period [20,21,22]. There was a significant weight loss in the first 3 months in patients who were enrolled in our study, which is consistent with data in the literature.…”

Section: Discussionsupporting

confidence: 80%

Obesity and Carpal Tunnel Syndrome: Is There a Causal Relationship?

Kurt

Kısacık²,

Kaplan

et al. 2008

Eur Neurol

View full text Add to dashboard Cite

Objectives: Obesity is defined as a risk factor for carpal tunnel syndrome (CTS). In this study, the presence or absence of recovery in median nerve conduction velocities after weight loss in obese patients was assessed in order to determine whether excess weight or other factors influence the higher prevalence of CTS in obese patients. Methods: Patients with body mass indexes (BMIs) ≧30 were included in the study. CTS symptoms, age, gender, height, body weight, and concomitant diseases were evaluated. Nerve conduction studies (NCS) were obtained on one upper extremity. All patients were included in dietetic programs. Three months later, NCS were repeated and compared with the first NCS. Results: BMIs were statistically significantly lower on the second visits 3 months later (p = 0.0001). No statistically significant difference was observed in the second NCS of electromyographically diagnosed cases with CTS (p > 0.05). Conclusion: We expected a recovery in median nerve conduction velocities in patients with CTS after weight loss. In the literature, even in untreated cases with CTS, spontaneous improvements in second NCS have been reported. This finding suggests that factors other than excess body weight may be influential in the higher prevalence of CTS in obese patients. A more detailed, genetic-factor-targeted investigation may prove more beneficial to clarify this issue.

show abstract

Section: Discussionsupporting

confidence: 80%

Obesity and Carpal Tunnel Syndrome: Is There a Causal Relationship?

Kurt

Kısacık²,

Kaplan

et al. 2008

Eur Neurol

View full text Add to dashboard Cite

show abstract

“…Orlistat improves adipocyte factors associated with hypertension, such as adiponectin, free fatty acids, IL-6, and leptin [64][65][66][67][68][69][70], and, clinically, orlistat improves blood pressure [72][73][74][75]. Orlistat improves adipocyte factors associated with dyslipidemia, such as adiponectin and free fatty acids [64,65,67,68] and, clinically, orlistat improves lipid blood levels [66,72,73,76,77].…”

Section: Treatment Of Adiposopathymentioning

confidence: 93%

“…Physiologically, weight loss with orlistat [62•,63] has favorable effects upon adipocyte factors associated with T2DM, such as adiponectin, free fatty acids, IL-6, leptin, resistin, and tumor necrosis factor-α [64][65][66][67][68][69][70], and, clinically, orlistat improves glucose metabolism [66,[71][72][73]. Orlistat improves adipocyte factors associated with hypertension, such as adiponectin, free fatty acids, IL-6, and leptin [64][65][66][67][68][69][70], and, clinically, orlistat improves blood pressure [72][73][74][75].…”

Section: Treatment Of Adiposopathymentioning

confidence: 99%

Adiposopathy is a more rational treatment target for metabolic disease than obesity alone

Bays

Dujovne²

2006

Curr Atheroscler Rep

View full text Add to dashboard Cite

Current guidelines recommend that weight-loss therapy should be primarily based upon specific body mass index (BMI) cut-off limits. However, in the adipocentric paradigm, it is acknowledged that co-morbidities, such as type 2 diabetes mellitus, hypertension, and dyslipidemia, occur at all levels of BMI. Excessive fat mass (adiposity) in genetically susceptible individuals results in fat dysfunction (adiposopathy), which then contributes to metabolic disorders that increase the risk of atherosclerotic cardiovascular disease. In this paradigm, the term "anti-obesity" treatment might best be replaced by "anti-adiposopathy" treatment, wherein the focus is not based solely on BMI, but instead directed towards physiologically improving fat cell function and clinically improving the metabolic health of patients. This may occur through appropriate diet, physical exercise, and other lifestyle changes, and/or from drug therapies. Cannabinoid receptor antagonists and peroxisome proliferator activated receptor agonists are examples of agents that physiologically improve fat function and clinically improve metabolic disease.

show abstract

“…To review further, Table 1 [6,8,[9][10][11][12][13][14][15][16] gives an overview of 10 randomized controlled trials in patients with T2D that reported research findings of benefits for the orlistat-treated group. Trials are listed by the length of time to the outcome measurement (6 months to 1 year).…”

Section: Obesity Trialsmentioning

confidence: 98%

Orlistat: Current issues for patients with type 2 diabetes

Mancino

2006

Curr Diab Rep

View full text Add to dashboard Cite

Orlistat, a pancreatic lipase inhibitor, was approved by the US Food and Drug Administration (FDA) in the spring of 1999 as an adjunct to lifestyle intervention for weight loss. This paper seeks to examine current issues regarding orlistat use in patients with type 2 diabetes. There are a number of trials that demonstrate the benefits of orlistat over placebo for reducing body weight and improving other health parameters. Of some interest are the preliminary explorations of interaction on cytokine levels, where a possible cardiovascular benefit is plausible. Implications of the FDA approval of over-the-counter use and the pharmaceutical development of another lipase inhibitor are also examined.

show abstract

Effects of orlistat on obesity‐related diseases – a six‐month randomized trial

Abstract: Orlistat plus a mildly reduced-calorie diet produced clinically meaningful weight loss and improvements in risk factors in overweight and obese patients with poorly controlled type 2 diabetes, hypertension or hypercholesterolaemia.

Cited by 36 publications

References 22 publications

Obesity and Carpal Tunnel Syndrome: Is There a Causal Relationship?

Obesity and Carpal Tunnel Syndrome: Is There a Causal Relationship?

Adiposopathy is a more rational treatment target for metabolic disease than obesity alone

Orlistat: Current issues for patients with type 2 diabetes

Contact Info

Product

Resources

About